The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans
Authors:
Open Access
- 14 June 2022
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 50 (8) , 1106-1118
Abstract
Abrocitinib is an oral once-daily Janus kinase 1 selective inhibitor being developed for the treatment of moderate-to-severe atopic dermatitis. This study examined the disposition of abrocitinib in male participants following oral and intravenous administration using accelerator mass spectroscopy methodology to estimate pharmacokinetic parameters and characterize metabolite profiles. The results indicated abrocitinib had a systemic clearance of 64.2 L/h, a steady state volume of distribution of 100 L, extent of absorption >90%, time to maximum plasma concentration of ≈0.5 hour, and absolute oral bioavailability of 60%. The half-lifeof both abrocitinib and total radioactivity was similar with no indication of metabolite accumulation. Abrocitinib was the main circulating drug species in plasma (≈26%) with 3 major mono-hydroxylated metabolites (M1, M2, and M4) at >10%. Oxidative metabolism was the primary route of elimination for abrocitinib with the greatest disposition of radioactivity shown in the urine (≈85%). In vitro phenotyping indicated abrocitinib cytochrome P450 fraction of metabolism assignments of 0.53 for CYP2C19, 0.30 for CYP2C9, 0.11 for CYP3A4, and ≈0.06 for CYP2B6. The principal systemic metabolites M1, M2, and M4 were primarily cleared renally. Abrocitinib, M1, and M2 showed pharmacology with similar Janus kinase 1 selectivity, whereas M4 was inactive. Significance Statement This study provides a detailed understanding of the disposition and metabolism of abrocitinib, a JAK inhibitor for atopic dermatitis, in humans, as well as characterization of clearance pathways and pharmacokinetics of abrocitinib and its metabolites.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic DermatitisJAMA Dermatology, 2019
- Cytokine modulation of atopic itchCurrent Opinion in Immunology, 2018
- Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation studyBritish Journal of Clinical Pharmacology, 2018
- Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension HepatocytesDrug Metabolism and Disposition, 2017
- Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay MethodDrug Metabolism and Disposition, 2016
- Automated Combustion Accelerator Mass Spectrometry for the Analysis of Biomedical Samples in the Low Attomole RangeAnalytical Chemistry, 2014
- Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem CellsStem Cells, 2014
- Which Human Metabolites Have We MIST? Retrospective Analysis, Practical Aspects, and Perspectives For Metabolite Identification and Quantification in Pharmaceutical DevelopmentChemical Research in Toxicology, 2009
- A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1′,1″-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6Drug Metabolism and Disposition, 2007
- Determination of mean valproic acid serum level by assay of a single pooled sampleClinical Pharmacology & Therapeutics, 1981